The Readout Loud

324 Episodes

1. 302: Vertex's big deal, biotech's red numbers, & an industry history lesson

   Published: 11/04/2024
2. 301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise

   Published: 04/04/2024
3. 300: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech

   Published: 28/03/2024
4. 299: Live! From the STAT Breakthrough Summit East

   Published: 21/03/2024
5. 298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard

   Published: 14/03/2024
6. 297: VC turmoil, GLP-1 competition, & the war on recovery

   Published: 07/03/2024
7. 296: Legal insider trading, booming biotech stocks, & the next GLP-1

   Published: 29/02/2024
8. 295: Humira’s legacy, CEO symbolism, and genomic surgery

   Published: 22/02/2024
9. 294: Pharma goes to Washington, Alnylam's future, & Gilead's dealmaking

   Published: 15/02/2024
10. 293: AI in medicine, detangling hype, and Icelandic DNA

    Published: 08/02/2024
11. 292: Vertex's polarizing data, Aduhelm's adieu, & an FDA icon

    Published: 01/02/2024
12. 291: The plight of the VC, Gilead's latest setback, & more M&A

    Published: 25/01/2024
13. 290: Biotech layoffs, slumping stocks, and a 2024 preview

    Published: 18/01/2024
14. 289: Live! From #JPM24

    Published: 11/01/2024
15. 287: 2023 in review, CEO report cards, and a look at the year ahead

    Published: 21/12/2023
16. 286: FTC v. biotech, Pfizer's kitchen sink, & Vertex's future

    Published: 14/12/2023
17. 285: CRISPR history, biotech struggles, & a big week for deals

    Published: 07/12/2023
18. 284: AbbVie’s big deal, CAR-T’s risks, & getting a biotech job

    Published: 30/11/2023
19. 283: A CRISPR milestone, algorithms amok, & biotech mixology

    Published: 16/11/2023
20. From Tradeoffs: Can the U.S. put an end to surprise ambulance bills?

    Published: 13/11/2023